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SUMMARY
Estimates of the number of hospitalizations attributable to specific pathogens are required to
predict the potential impact of vaccination. All hospital admissions for lower respiratory tract
infection (LRI) in children ! 5 years in England in 1995–8 were reviewed. Most admissions
(76–8%) were not associated with specific organisms. Seasonality in pathogens that cause
bronchiolitis and pneumonia was used to predict the proportion of cases with unspecified
aetiology attributable to different organisms using multiple linear regression. Of 12298
admissions for LRI, 17–5% were due to RSV infection. An estimated 74–8% (95% CI,
72–0–77–7%) of ‘unspecified bronchiolitis ’ admissions and 16–3% (95% CI, 13–7–18–8%) of
‘unspecified pneumonia’ admissions were RSV related. The total mean annual incidence of
hospital admissions attributable to RSV is 28–3}1000 children ! 1 year of age, and 1–3}1000
children 1–4 years old. The greater burden of RSV infection than indicated through discharge
data is revealed through applying simple statistical methods.
INTRODUCTION
Respiratory syncytial virus (RSV) is the most common
cause of lower respiratory tract infection (LRI) in
infants and children worldwide. Epidemics occur
yearly during winter and early spring in temperate
climates. RSV has a variety of clinical and epi-
demiological manifestations in different age groups.
Despite the presence of maternal antibodies, severe
clinical manifestations (typically pneumonia and
bronchiolitis) often resulting in hospitalization most
commonly occur among infants aged less than 6
months. The risk of serious RSV disease is markedly
increased for children born prematurely or with
underlying chronic lung disease such as broncho-
pulmonary dysplasia [1]. Nearly all children are
* Author for correspondence.
infected by 2 years of age. However, since the virus
inducespoorprotective immunity, reinfection through-
out life is common. Thus RSV is increasingly
recognized as an important cause of otitis media in
older children [2] and of serious respiratory disease in
the elderly and immunocompromised individuals
[3–5].
There have been a number of recent potential
therapeutic developments : immunoprophylaxis with
RSV specific immune globulin or monoclonal anti-
bodies targeted at high-risk infants. After the failure
of a formalin-inactivated vaccine in the early 1960s,
which induced an exaggerated clinical response to
wild type RSV infection in infants, there are currently
no safe and effective vaccines licensed. However, two
approaches are being evaluated in clinical trials :
subunit vaccines for immunization of older children
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with underlying chronic lung disease and the elderly,
and live attenuated vaccines for infants [6].
In the United Kingdom, Sims et al. [7] reported
over 25 years ago that the risk of hospital admission
with RSV in the first year of life in northeast England
was 20 per 1000 per year. More recent UK studies
have been undertaken in cohorts of pre-term infants
and those with underlying chronic lung disease
to determine the potential impact of immuno-
prophylaxis. They reported an annual incidence of
hospitalization for confirmed RSV infection of 36–41
admissions per 1000 at risk infants [8, 9]. However,
serious RSV disease and consequently hospitalization
can occur in otherwise healthy infants as well as in
high-risk children. With recent advances in vaccine
development it is crucial to obtain an update of the
burden of RSV in both groups to determine the most
appropriate vaccination strategy.
In this study we examine all hospitalizations for
LRI in England over a 3-year period to try and
determine hospitalization rates in those under 5 years
of age. However, in common with most surveillance
data, which rely on clinical reports for which
laboratory data are not complete, a large number of
hospitalizations are recorded at the syndromic level
(e.g. unspecified pneumonia). This poses a problem
when trying to ascertain the burden of particular
aetiological agents. Previous authors have often used
rather crude assumptions; such as all bronchiolitis
cases are due to RSV. In this paper we use a simple
statistical technique to estimate what proportion of
these hospitalizations of young children with LRI can
be attributed to specific aetiological agents, thereby
providing a baseline for an evaluation of the potential
health and economic impact of RSV vaccination as
new vaccines become available.
METHODS
Data source
The details of patients admitted to hospital with a
diagnosis of LRI (definition given below) were
obtained from the hospital episodes statistic (HES)
database from April 1995 through March 1998. HES
contained personal, medical and administrative details
of all patients admitted to NHS hospitals in England,
a population of approximately 49 million people.
HES records included information on patient’s age,
sex, dates of admission}discharge, number of bed
days, and outcome. As data also contain personal
identifiers such as date of birth and postal code,
duplicates could be identified and excluded. Hos-
pitalization rates were calculated using denominators
derived from the annual resident population estimates
based on the projections of the 1991 UK census
(Office for National Statistics).
All admissions with an International Classification
of Diseases 10th Revision (ICD-10) code associated
with LRI in any of the seven diagnostic fields for each
record were included in the analysis. The following
codes were used to cover all causes of LRI: pneumonia
(J12–18), acute bronchitis (J20), acute bronchiolitis
(J21), unspecified acute lower respiratory infection
(J22), bronchitis, not specified as acute or chronic
(J40), influenza (J10, J11), other chronic obstructive
pulmonary disease with acute lower respiratory tract
infection}acute exacerbation, unspecified (J44),
whooping cough (A37), Legionnaires’ disease (A48),
Chlamydia psittaci infection (A70), and congenital
pneumonia (infective) (P23).
To determine the proportion of patients hos-
pitalized due to RSV who were in ‘high risk’,
premature birth and underlying chronic respiratory
disease categories were specifically ascertained among
the hospitalized children under 5 years of age. The
following ICD-10 codes were used to define HES
records associated with high-risk status : gestation
before 37th week (P07), respiratory distress of
newborn (P22), congenital pneumonia (P23), neonatal
aspiration syndromes (P24), respiratory disease orig-
inating in the perinatal period (which includes
bronchopulmonary dysplasia) (P27}P28), congenital
malformations of trachea, bronchus, lung (Q32}Q33),
chronic obstructive pulmonary disease (J44), and
cystic lung disease (J98.4). For ease of presentation the
term ‘low risk’ is used for patients who did not have
one of the above codes recorded.
Statistical analysis
No aetiological cause was recorded for a large number
of LRI admissions (termed here ‘unspecified LRI’).
Multiple linear regression analysis was used to
estimate the contribution of RSV and other aetio-
logical agents of lower respiratory tract illnesses to
hospital admissions in children coded as ‘unspecified
LRI’, following the method of Ryan et al. [10]. The
technique uses the observed temporal variation in
potential causative agents of the clinical outcome (in
this case pneumonia and bronchiolitis of unspecific
aetiological cause) to estimate the level of under-
diagnosis for each of these causes.
Because there are two clinical syndromes with
differing patterns of possible infectious cause, two
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Table 1. Number and diagnosis of lower respiratory tract infection (LRI )-
associated hospitalizations in children ! 5 years of age England,
4}95–3}98
Diagnosis
No. of
admissions %
Unspecified LRI, of those: 97783 76–8
Pneumonia 52107
Bronchiolitis 42350
Bronchitis 2673
Influenza (virus not identified) 620
Chronic obstructive pulmonary disease 8
Mixed (" 1 unspecified LRI) 25
RSV 22229 17–5
Bordetella spp. 3155 2–5
Streptococcus pneumoniae 915 0–7
Mycoplasma pneumoniae 691 0–5
Parainfluenza 434 0–3
Influenza 275 0–2
Dual infections 163 0–1
Haemophilus influenzae 158 0–1
Other (allergic asthma, Chlamydia spp.,
enterovirus, Klebsiella pneumoniae,
staphylococcus, streptococcus group B)
1495 1–2
Total 127298 100–0
Table 2. Children hospitalized with reported RSV
infection who are classed as ‘high-risk ’ patients
! 1 year
(nfl 20310)
1–4 years
(nfl 1919)
‘High risk’ of those 382 (1–9%) 77 (4–2%)
Preterm 133 (35%) 8 (10%)
Underlying chronic
respiratory disease
249 (65%) 69 (90%)
models were developed for the regression analysis
using different dependent variables ; model 1, for
unspecified bronchiolitis (ICD-10: J21.9) and model 2
for unspecified pneumonia (ICD-10: J12.8}9;
J15.8}9; J18. Both models used the weekly number of
admissions in children under 5 years of age for the
respective ICD-10 diagnoses. The independent vari-
ables were the weekly numbers of the following
recorded causes of LRI-associated hospital ad-
missions:
E RSV (ICD-10: J12.1; J20.5 ; J21.0)
E Streptococcus pneumoniae (ICD-10; J13)
E Influenza (ICD-10: J10)
E Parainfluenza (ICD-10: J12.2; J20.4 ; J05.0)
E Bordetella species (ICD-10: A37)
E Haemophilus influenzae (ICD-10: J14; J20.1)
E Mycoplasma pneumoniae (ICD-10: J15; J 20.0)
We also defined a variable named ‘other ’ which
included LRI-associated admissions due to pathogens
or diseases for which either the total number of
admissions was under 100 (Klebsiella pneumoniae,
staphylococci, streptococci group B, chlamydial pneu-
monia, Legionnaires’ disease, rhinovirus) or were too
heterogeneous to analyse them separately (allergic
asthma, nonallergic asthma, mixed asthma). Patients
of all age groups were combined for the independent
variables, as there was no difference in seasonal
patterns between younger and older age groups and
using all ages made the seasonal trends more distinct.
A backward stepwise regression was performed to
remove variables that did not contribute to the model
using SPSS 10.0 for Windows (SPSS Inc., Chicago,
IL, USA). In a step-by-step procedure single variables
that reduced R# by the smallest increment were
removed from the equation if the resulting decrease
was not statistically significant by the F test (signifi-
cance level of F value ! 0–05). The procedure was
continued until the removal of a variable caused a
significant reduction in R#. Analysis of residual plots
was performed to assess the validity of the model and
evidence for autocorrelation. The likely impact of
possible model misspecification was investigated by
examining the changes in coefficients of the final
model to sequential deletion of significant variables.
Differences in the length of stay (number of bed
days) between the ‘high risk’ RSV patients and RSV
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Table 3. Spell duration of ‘high risk ’ and ‘ low risk ’ children hospitalized
with reported RSV infection
! 1 year 1–4 years
‘High risk’
(nfl 382)
‘Low risk’
(nfl 19928)
‘High risk’
(nfl 77)
‘Low risk’
(nfl 1842)
Known spell duration 90% 98% 94% 99%
Median (mean) no. of days 8 (16) 3 (4) 7 (20) 3 (4)
Range 0–243 0–305 0–560 0–478
patients with no code for high risk (‘ low risk’) were
compared by using the Wilcoxon rank sum test. We
used the Fisher’s exact test to assess whether there was
a difference in mortality between the two groups.
RESULTS
LRI admissions in children
Between April 1995 and March 1998, 127298 children
under 5 years of age were admitted to hospital with a
diagnosis of LRI in England. Of these, 17–5% of the
hospital admissions were coded as ‘LRI due to RSV’,
76–8% as ‘LRI due to unspecified organism’ and the
remaining 5–7% were due to other specified causes.
Table 1 shows the numbers and diagnosis of the
hospitalized children. Of the 97783 children under 5
years of age admitted due to an unspecified LRI,
53–3% were diagnosed with pneumonia, 43–3% with
bronchiolitis, 2–7% with bronchitis, and 0–6% with
influenza (virus not identified). Less than one percent
of the children was diagnosed with more than one
unspecified LRI, and unspecified chronic obstructive
pulmonary disease, respectively. Sixty-four percent of
all hospitalizations were in children younger than 1
year. The sex distribution was 58% male, 41% female
and 1% non-reported.
RSV admissions in children
Of the 22229 hospital admissions coded as due to
RSV infection during the 3-year study period, 91–3%
(nfl 20310) were children younger than 1 year and
65–9% (nfl 14639) were under 6 months of age.
Ninety-seven percent (nfl 21554) of all RSV patients
were diagnosed with bronchiolitis, 1–9% (nfl 416)
with bronchitis, and 1–1% (nfl 243) with pneumonia.
The proportion of reported ‘high-risk’ patients was
4% (nfl 77) among the RSV-associated hospitalized
children aged 1 to 4 years, whereas for children under
1 year, 1–9% (nfl 382) met the criteria for ‘high-risk’
patients (Table 2). The number of bed days was
significantly higher at P! 0–001 (Wilcoxon rank sum
test) in ‘high-risk’ patients in both age groups (8 bed
days for children ! 1 year and 7 for children aged 1–4
years) compared with the corresponding ‘ low risk’
patients (3 and 3 bed days respectively) (Table 3). The
proportion of ‘high risk’ RSV infants who died was
significantly higher compared to ‘ low risk’ (3–3% s.
0–2%) (proportions P! 0–001, Fisher’s exact test).
There was evidence for increased mortality amongst
‘high risk’ patients aged 1–4 years, though the
difference was not significant at the 5% level (Pfl
0–093) (Table 4).
Temporal trends in LRI admissions
The models we constructed used the patterns of
seasonal variation in the weekly number of admissions
for each known cause of LRI. Figure 1 shows the
seasonal variation of weekly admissions due to RSV,
influenza, S. pneumoniae, H. influenzae, M. pneu-
moniae, ‘other ’, Bordetella spp., and parainfluenza in
all age groups during the 3-year study period.
The weekly number of RSV admissions peaked
sharply annually during the winter months.
Admissions due to influenza and S. pneumoniae also
peaked clearly in winter but their peaks varied more
than that of RSV over the study period, and a large
number of hospitalization due to S. pneumoniae
occurred in spring and early summer. Admissions
associated with H. influenzae and M. pneumoniae and
‘other ’ also peaked in winter but did not show such
distinct seasonal patterns. Bordetella spp. has 3–4 year
epidemic cycles and reports increased steadily to a
peak in 1998 but also with annual peaks in late
summer}autumn. Parainfluenza showed no clear
seasonal variation.
Estimated hospitalization rates
Using our final models, the weekly number of
unspecified bronchiolitis and unspecified pneumonia
hospitalizations due to RSV and the other respiratory
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Table 4. Mortality of ‘high risk ’ and ‘ low risk ’ children hospitalized with
reported RSV infection
! 1 year 1–4 years
‘High risk’
(nfl 382)
‘Low risk’
(nfl 19928)
‘High risk’
(nfl 77)
‘Low risk’
(nfl 1842)
Known method of discharge 96% 99% 97% 99%
Died 12 (3–3%) 38 (0–2%) 2 (2–7%) 11 (0–6%)
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Fig. 1. Seasonality of weekly hospital admissions in all patients for LRI due to RSV, influenza, S. pneumoniae, M.
pneumoniae, Bordetella spp., parainfluenza, H. influenzae, and ‘other ’, England, April 1995–March 1998.
pathogens were estimated. Figures 2 and 3 show that
these estimates correspond closely with the observed
weekly numbers. Derived from these estimates the
proportion of unspecified bronchiolitis and un-
specified pneumonia accounted for by these organisms
were calculated (Tables 5, 6).
Seventy-five percent (95% CI, 72–0–77–7%) of the
‘unspecified bronchiolitis ’ admissions and 16–3%
(95% CI, 13–7–18–8%) of the ‘unspecified pneumonia’
admissions in children younger than 5 years of age
were RSV related. This results in a total (observed›
expected) mean annual incidence of hospital ad-
missions attributable to RSV of 1–3 per 1000 among
children aged 1–4 years, and of 28–3 per 1000 for
children under 1 year of age during the 3-year study
period.
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Fig. 2. Comparison of observed weekly number of un-
specified bronchiolitis hospitalizations in children ! 5 years
of age with estimated weekly number due to RSV, influenza,
and parainfluenza based on the final model
bronchiolitis
shown
in Table 5.
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Fig. 3. Comparison of observed weekly number of un-
specified pneumonia hospitalizations in children ! 5 years
of age with estimated weekly number due to RSV, influenza,
and parainfluenza, S. pneumoniae, and M. pneumoniae
based on the final model
pneumonia
shown in Table 6.
Table 5. Estimates of the proportion (%) of
unspecified bronchiolitis hospitalizations in children
! 5 years of age due to specific respiratory
pathogens and sensitiity of results to model
specification
Pathogen
Final model
Model 1
bronchiolitis
Model 2
bronchiolitis
RSV 74–8 79–9
Influenza 10–1 —
Parainfluenza 12–7 —
Intercept 2–4 20–1
Adjusted R# 0–965 0–955
The adjusted R#s of both final models indicate that
97% and 80% of the variation in the weekly number
of unspecified cases was explained by model 1
bronchiolitis
and by model 1
pneumonia
respectively. Furthermore, we
checked model 1
bronchiolitis
for confounding (Table 5)
as RSV and influenza have quite similar seasonality
and parainfluenza showed no clear seasonal pattern.
Any possible bias seemed to be negligible as dropping
the two significant variables from the model 1
bronchiolitis
lead to only 5% increase in the estimated proportion
of RSV (model 2
bronchiolitis
). In model 1
pneumonia
(Table
6) M. pneumoniae accounted for 17–5% of the
unspecified pneumonia admissions – more than ex-
pected, consequently ‘Mycoplasma pneumoniae ’ was
dropped to check the robustness of the estimates
(model 2
pneumonia
). There was little change in the
remaining estimated proportions and the model fit
was no better. In a third model (model 3
pneumonia
), we
excluded the intercept to determine if we could obtain
a better model fit. There was a large increase in the
estimated proportion due to S. pneumoniae and
M. pneumoniae. However, a slight decrease in the
adjusted R# value was observed, suggesting poorer fit.
Consequently, model 1
pneumonia
was used to obtain
the estimated hospitalization rates.
DISCUSSION
Our study estimates the annual incidence of hospital
admissions attributable to RSV and other causes of
LRI in children using a regression modelling ap-
proach. This technique uses the observed temporal
trends in potential causative agents of LRI to estimate
the contribution of each of these agents to ‘un-
specified’ hospitalizations. These estimates of hos-
pitalizations due to RSV together with the cases
actually coded as RSV-associated hospitalizations
represent 49% of all annual LRI admissions in
children under 5 years of age in England. As expected
for an illness with most severe manifestations in
infants the estimated incidence of RSV-associated
hospitalization was higher in children under 1 year of
age accounting for 65% of all annual LRI admissions
in England in this age group. There is a greater burden
of RSV infection than indicated through current
routine data (HES) in England. The findings suggest
that in many cases RSV is not identified despite the
availability of ICD10 codes in hospital records for
RSV, and thus the illness is assigned a non-specific
code for LRI.
Our results are in accordance with findings in a
descriptive analysis of US National Discharge Survey
data from 1980 through 1996 [11]. All discharge
records from children younger than 5 years of age
with an ICD-9 code (ICD-10 codes were not in-
troduced until April 1995) for any respiratory illness
among the diagnoses listed were selected for this
study. Due to lack of a specific ICD-9 code for RSV-
associated disease, the authors were forced to use the
proportion of bronchiolitis from November through
April as a rather crude proxy for RSV-associated
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Table 6. Estimates of the proportion (%) of unspecified pneumonia
hospitalizations in children ! 5 years of age due to specific respiratory
pathogens and sensitiity of results to model specification
Pathogen
Final model
Model 1
pneumonia
Model 2
pneumonia
Model 3a
pneumonia
RSV 16–3 16–5 15–1
Influenza 7–0 8–3 4–8
Parainfluenza 12–9 14–0 14–8
S. pneumoniae 19–8 23–0 33–5
M. pneumoniae 17–5 — 31–8
Intercept 26–6 38–2 —
Adjusted R# 0–799 0–789 0–774
a Regression through the origin (no-intercept model).
hospitalizations. This study suggested RSV was
responsible for 50–80% of annual LRI hospital-
izations among children younger than 1 year. We have
used specific ICD-10 codes for RSV-associated hos-
pitalizations. Furthermore, our regression analysis
made use of the temporal patterns of all of the most
important respiratory pathogens over the entire 3-
year study period, which makes our estimates more
robust.
The hospitalization rate of 20 per 1000 per year in
children younger than 1 year of age found in 1975 [7]
by taking specimens from all children admitted to a
paediatric ward with a respiratory tract illness in
north-east England is approximately 50% lower than
the rate derived from our estimates. However, a
substantial increase in rates of hospitalization of
infants with bronchiolitis during 1980–96 was also
seen in an American study [11]. Furthermore, at-
tendance at a child-care centre is considered to be an
independent risk factor for LRI hospitalization in
children under 2 years of age [12]. Thus the trend
toward earlier enrolment in nurseries may lead to
initial RSV infection at a younger age when severe
disease and consequently hospitalization is more
likely. Improved survival rates of premature infants
may also have contributed to increases in RSV
hospitalization rates over the last 20 years.
Previous studies have suggested that ‘high risk’
infants are the most important target group for
intervention strategies [13–15]. Our data suggest that
the majority (98%) of children under 1 year of age
hospitalized with reported RSV infection are not
‘high risk’ (i.e. concurrently diagnosed with prema-
turity or underlying chronic lung disease). Our data
show that spell duration and mortality is significantly
higher in ‘high risk’ RSV patients but the major
caseload of RSV occurred in otherwise healthy
children. However, it is very likely that the in-
formation needed for defining patients as ‘high risk’
(gestation age, underlying medical conditions) were
underreported in the HES records and we thus
underestimate the proportion of ‘high-risk’ patients.
Buck et al. (16) report that ex-preterm infants under 6
months of age and those with bronchopulmonary
dysplasia accounted for 8% and 10% respectively of
RSV positive admissions to the paediatric department
in Cambridge, England, during the winters 1998}9
and 1999}2000.
Our method has potential limitations. As the
regression models relied on the temporal pattern of in
potential causative agents of LRI, a proportion of
cases could be attributed to other pathogens with
similar patterns, which we did not consider as
variables in the models. Van den Hoogen et al. [17]
described recently the characterization of a new
member in the Paramyxoiridae family, isolated from
28 children with LRI over a period of 20 years. The
clinical symptoms were reminiscent of those caused by
RSV infection, although the seasonal pattern is still
unclear. However, we examined all the major known
infectious and non-infectious causes of respiratory
illness in children. Secondly, RSV-associated hos-
pitalizations may have been underestimated, because
we were not able to estimate the proportion of
‘unspecified bronchitis ’ hospitalizations related to
RSV due to lack of data and consequently no clear
seasonal pattern. Yet these represent a minority of
LRI admissions in young children. Also, only
admissions associated with LRI were included in the
analysis, as RSV is not thought to cause any non-LRI
syndromes in children unlike other causes of LRI such
as influenza or S. pneumoniae. Estimates for hospital-
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izations due to the latter organisms must take
diagnoses such as febrile illnesses, septicaemia etc. in
account.
In summary, our data suggest a large burden of
LRI is due to RSV in young children and that the
introduction of a safe and effective RSV vaccine could
greatly reduce the number of hospitalizations. To
determine which vaccination strategy (a high risk,
targeted approach or a general population approach)
should potentially be implemented, the possible
contribution of underlying conditions, including
premature birth, to the incidence of RSV hospital-
izations in children needs to be more fully ascertained.
We have shown that data on hospital admissions
can be analysed in a simple regression model to get a
better estimate of the incidence of RSV-associated
hospitalization in children and that this method is a
useful tool to estimate the level of under-diagnosis of
potential aetiological causes in non-specific clinical
outcomes.
ACKNOWLEDGEMENTS
The authors thank Tom Nichols for technical as-
sistance, and Dr Richard Pebody and Dr John Watson
for valuable comments on previous versions of the
manuscript.
REFERENCES
1. Groothuis JR, Gutierrez KM, Lauer BA. Respiratory
syncytial virus infection in children with broncho-
pulmonary dysplasia. Pediatrics 1988; 82 : 199–203.
2. Anderson LJ. Respiratory syncytial virus vaccines for
otitis media. Vaccine 2001; 19 : 59–65.
3. Falsey AR, Treanor JJ, Betts RF, Walsh EE. Viral
respiratory infections in institutionalized elderly : clini-
cal and epidemiological findings. J Am Geriatrics Soc
2001; 40 : 115–9.
4. Sorvillo FJ, Huie SF, Strassburg MA, Butsumyo A,
Shandera WX, Fannin SL. An outbreak of respiratory
syncytial virus pneumonia in a nursing home for the
elderly. J Infect 1984; 9 : 252–6.
5. Falsey AR, Walsh EE. Respiratory syncytial virus
infections in adults. Clin Microbiol Rev 2000; 13 :
372–84.
6. Dudas RA, Karron RA. Respiratory syncytial virus
vaccines. Clin Microbiol Rev 1998; 11 : 430–9.
7. Sims DG, Downham MA, McQuillin J, Gardner PS.
Respiratory syncytial virus infection in north-east
England. BMJ 1976; 2 : 1095–8.
8. Thomas M, Bedford-Russell A, Sharland M. Hospital-
ization for RSV infection in ex-preterm infants –
implications for use of RSV immune globulin. Arch
Dis Child 2000; 83 : 122–7.
9. Clark SJ, Beresford MW, Subhedar NV, Shaw NJ.
Respiratory syncytial virus infection in high risk infants
and the potential impact of prophylaxis in a United
Kingdom cohort. Arch Dis Child 2000; 83 : 313–6.
10. Ryan MJ, Ramsay M, Brown D, Gay NJ, Farrington
CP, Wall PG. Hopital admissions attributable to
rotavirus infection in England and Wales. J Infect Dis
1996; 174 (Suppl. 1) : S12–8.
11. Shay DK, Holman RC, Newman RD, Liu LL, Stout
JW, Anderson LJ. Bronchiolitis-associated hospital-
izations among US children, 1980–1996. JAMA 1999;
282 : 1440–6.
12. Anderson LJ, Parker RA, Strikas RA et al. Day care
attendance and hospitalization for lower respiratory
tract illness. Pediatrics 1988; 82 : 300–8.
13. Groothuis JR, Simoes EAF, Levin MJ et al. Prophy-
lactic administration of respiratory syncytial virus
immune globulin to high-risk infants and young
children. N Engl J Med 1993; 329 : 1524–30.
14. PREVENT Study Group. Reduction of respiratory
syncytial virus hospitalization among premature infants
and infants with bronchopulmonary dysplasia using
respiratory syncytial virus immune globulin prophy-
laxis. Pediatrics 1997; 99 : 93–9.
15. Impact-RSV Study Group. Palivizumab, a humanized
respiratory syncytial virus monoclonal antibody,
reduces hospitalization from respiratory syncytial virus
infection in high-risk infants. Pediatrics 1998; 102 :
531–7.
16. Buck JJ, Debenham P, Tasker RC. Prophylaxis for
respiratory syncytial virus infection: missing the target.
Arch Dis Child 2001; 84 : 375.
17. Van den Hoogen BG, de Jong JC, Groen J, et al. A
newly discovered human pneumovirus isolated from
young children with respiratory tract disease. Nature
Medicine 2001; 7 : 719–24.
